中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2013年
20期
17-20
,共4页
肺肿瘤%杀伤细胞%T淋巴细胞亚群
肺腫瘤%殺傷細胞%T淋巴細胞亞群
폐종류%살상세포%T림파세포아군
Lung neoplasms%Killer cells%T-lymphocyte subsets
目的 探讨细胞因子激活的杀伤细胞(CIK)对局部晚期非小细胞肺癌同步放化疗患者T淋巴细胞亚群及自然杀伤细胞(NK)的影响.方法 将61例局部晚期非小细胞肺癌患者应用抽签法随机分为治疗组和对照组,治疗组31例,先给予三维适形放疗同步化疗,然后给予CIK回输治疗；对照组30例,给予三维适形放疗同步化疗.结果 治疗组治疗后CD3+、CD4+、CD4+/CD8+及CD16+ CD56+分别由0.6374±0.0325、0.3217±0.0287、0.0102±0.0093及0.1224±0.0177上升至0.7125±0.0154、0.3921±0.0461、0.0178±0.0179及0.1855±0.0321,CD8+由0.3147±0.0307下降至0.2209±0.0257,治疗前与治疗后比较差异有统计学意义(P＜0.05).对照组治疗后CD3+、CD4+、CD8+、CD4+/CD8+及CD16+ CD56+分别为0.6218±0.0040、0.3311±0.0278、0.3265±0.0257、0.0101±0.0108及0.1327±0.0298,与治疗前0.6325±0.0114、0.3347±0.0209、0.3316±0.0178、0.0101±0.0117及0.1479±0.0354比较差异无统计学意义(P＞0.05).治疗组和对照组不良反应发生率比较差异无统计学意义(P＞0.05).结论 CIK治疗可以改善局部晚期非小细胞肺癌患者机体的免疫功能.
目的 探討細胞因子激活的殺傷細胞(CIK)對跼部晚期非小細胞肺癌同步放化療患者T淋巴細胞亞群及自然殺傷細胞(NK)的影響.方法 將61例跼部晚期非小細胞肺癌患者應用抽籤法隨機分為治療組和對照組,治療組31例,先給予三維適形放療同步化療,然後給予CIK迴輸治療；對照組30例,給予三維適形放療同步化療.結果 治療組治療後CD3+、CD4+、CD4+/CD8+及CD16+ CD56+分彆由0.6374±0.0325、0.3217±0.0287、0.0102±0.0093及0.1224±0.0177上升至0.7125±0.0154、0.3921±0.0461、0.0178±0.0179及0.1855±0.0321,CD8+由0.3147±0.0307下降至0.2209±0.0257,治療前與治療後比較差異有統計學意義(P＜0.05).對照組治療後CD3+、CD4+、CD8+、CD4+/CD8+及CD16+ CD56+分彆為0.6218±0.0040、0.3311±0.0278、0.3265±0.0257、0.0101±0.0108及0.1327±0.0298,與治療前0.6325±0.0114、0.3347±0.0209、0.3316±0.0178、0.0101±0.0117及0.1479±0.0354比較差異無統計學意義(P＞0.05).治療組和對照組不良反應髮生率比較差異無統計學意義(P＞0.05).結論 CIK治療可以改善跼部晚期非小細胞肺癌患者機體的免疫功能.
목적 탐토세포인자격활적살상세포(CIK)대국부만기비소세포폐암동보방화료환자T림파세포아군급자연살상세포(NK)적영향.방법 장61례국부만기비소세포폐암환자응용추첨법수궤분위치료조화대조조,치료조31례,선급여삼유괄형방료동보화료,연후급여CIK회수치료；대조조30례,급여삼유괄형방료동보화료.결과 치료조치료후CD3+、CD4+、CD4+/CD8+급CD16+ CD56+분별유0.6374±0.0325、0.3217±0.0287、0.0102±0.0093급0.1224±0.0177상승지0.7125±0.0154、0.3921±0.0461、0.0178±0.0179급0.1855±0.0321,CD8+유0.3147±0.0307하강지0.2209±0.0257,치료전여치료후비교차이유통계학의의(P＜0.05).대조조치료후CD3+、CD4+、CD8+、CD4+/CD8+급CD16+ CD56+분별위0.6218±0.0040、0.3311±0.0278、0.3265±0.0257、0.0101±0.0108급0.1327±0.0298,여치료전0.6325±0.0114、0.3347±0.0209、0.3316±0.0178、0.0101±0.0117급0.1479±0.0354비교차이무통계학의의(P＞0.05).치료조화대조조불량반응발생솔비교차이무통계학의의(P＞0.05).결론 CIK치료가이개선국부만기비소세포폐암환자궤체적면역공능.
Objective To observe the influence of T cell subsets and natural killer cell ofcytokine induced killer (CIK) therapy for partial advanced non-small cell lung cancer patients.Methods Sixty-one patients with partial advanced non-small cell lung cancer were randomly divided into treatment group and control group by sortition method.In treatment group,31 patients received three dimensional conformal radiation therapy and chemotherapy,then received CIK treatment.In control group,30 patients received three dimensional conformal radiation therapy and chemotherapy.Results In treatment group,CD3+,CD4+,CD4+/CD8+ and CD16+ CD56+ after treatment were significantly higher than before treatment (0.7125 ± 0.0154 vs.0.6374 ± 0.0325,0.3921 ± 0.0461 vs.0.3217 ± 0.0287,0.0178 ± 0.0179 vs.0.0102 ± 0.0093,0.1855 ± 0.0321 vs.0.1224 ± 0.0177),CD8+ after treatment was significantly lower than before treatment (0.2209 ± 0.0257 vs.0.3147 ± 0.0307),there was significant difference (P ＜ 0.05).In control group,there were no significant difference in CD3+,CD4+,CD8+,CD4+/CD8+ and CD16+ CD56+ between after treatment and before treatment (0.6218 ± 0.0040 vs.0.6325 ± 0.0114,0.3311 ± 0.0278 vs.0.3347 ± 0.0209,0.3265 ± 0.0257 vs.0.3316 ± 0.0178,0.0101 ± 0.0108 vs.0.0101 ± 0.0117,0.1327 ± 0.0298 vs.0.1479 ± 0.0354,P ＞ 0.05).The side effects in the treatment group and control group showed no significant difference (P ＞0.05).Conclusion CIK therapy can improve immune function in patients with partial advanced non-small cell lung cancer.
